Endometrial cancer is the most common gynecologic malignancy in the US

Icon: 1 out of 4 women

Approximately 1 out of 4 women with endometrial cancer have recurrent or advanced cancer. Recurrent or advanced means cancer has either returned or spread to other parts of the body.

The role of dMMR in endometrial cancer

dMMR, or mismatch repair deficiency, is an important biomarker in endometrial cancer

Biomarkers help your doctor diagnose cancer and decide which treatment option is right for you. Up to 30% of women with endometrial cancers have the dMMR biomarker.

Image: Portrait of woman 1

Knowing whether your endometrial cancer is dMMR can help your doctor choose the right treatment for you.

Your doctor can perform an IHC (immunohistochemistry) test that can tell if your endometrial cancer is dMMR. JEMPERLI has been shown to be effective against confirmed dMMR endometrial cancer that has advanced or returned and after chemotherapy containing platinum. If you have questions about dMMR and how JEMPERLI may help you, talk to your doctor today.

Icon: Lightbulb

How may JEMPERLI help?

See the Benefits of JEMPERLI

Icon: Gears

How may JEMPERLI fight cancer?

See How JEMPERLI Works